Unruptured Intracranial AneurysmChTUIANCT05844163
Treatment Strategies for Unruptured Intracranial Aneurysms in the Chinese Population China Treatment Trial for Unruptured Intracranial Aneurysm (ChTUIA)
An observational study of Unruptured Intracranial Aneurysm, run by Beijing Tiantan Hospital at 1 site in China.
Trial summary
The goal of this prospective observational cohort study is to learn about treatment strategies for unruptured intracranial aneurysms in the Chinese population. The main questions it aims to answer are: To establish a cohort of patients with intracranial unruptured aneurysm and explore the optimal clinical treatment… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Unruptured Intracranial Aneurysm
- What is being tested?
- observation
- How many people
- 31,595 participants
- Where
- 1 siteChina
- Study dates
- 1 Dec 2021to 1 Dec 2024
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with unruptured intracranial aneurysm
Who may be able to join
- age > 18 years. B. at least one intracranial aneurysm needs to be treated by craniotomy, endovascular treatment or combined surgery.
- patients' consent were obtained.
Who cannot join
- Ruptured intracranial aneurysms, accompanied by subarachnoid hemorrhage or cerebral hemorrhage ;
- Traumatic, infectious and atrial myxoma-associated intracranial aneurysms ;
- Combined with cerebrovascular malformations;
- Combined with brain tumors or malignant tumors in other parts ;
- Combined with systemic connective tissue disease and systemic rheumatic disease ;
- Due to other diseases, or poor general condition, the expected survival time is not more than 12 months ;
- During pregnancy and perinatal period.
Trial locations and contacts
1 site in 1 country.
China1 site
Capital Medical University Affiliated Beijing Tiantan Hospital
Beijing, Beijing Municipality
About this study
The goal of this prospective observational cohort study is to learn about treatment strategies for unruptured intracranial aneurysms in the Chinese population. The main questions it aims to answer are:
- To establish a cohort of patients with intracranial unruptured aneurysm and explore the optimal clinical treatment strategy.
- To establish clinical management path for patients with unruptured intracranial aneurysm.
According to the treatment of all patients with unruptured intracranial aneurysm, they were divided into the following groups: 1. Conservative treatment group; 2. Intracranial aneurysm clipping group; 3. Coil embolization or stent-assisted coil embolization group; 4. Flow diversion group.
- Conditions
- Unruptured Intracranial Aneurysm
- Being tested
- observation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
observationOther
observation
| Study group | Role | What they receive |
|---|---|---|
| Intracranial aneurysm clipping group | Patients in Intracranial aneurysm clipping group receive neurosurgical clipping. Receives: Other: observation | |
| Coil embolization or stent-assisted coil embolization group | Patients in coil embolization or stent-assisted coil embolization group receive coil embolization or stent-assisted coil embolization according to individualized condition. Receives: Other: observation | |
| Flow diversion group. | Patients in flow diversion group receive flow diverters. Receives: Other: observation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Outcome
Functional outcomes(modified Rankin Scale,mRS) at 2 years after treatment decision
Measured: 2 years
Secondary outcomes (6)
MACCE events
Incidence of major adverse cardiovascular/cerebrovascular events (MACCE events) in patients with atherosclerotic heart disease within 1 year after treatment decision.
Measured: 1 years
cardiovascular/cerebrovascular events
Incidence of cardiovascular/cerebrovascular events in 2 years after receiving different treatment strategies.
Measured: 2 years
Cost
Costs associated with unruptured intracranial aneurysms within 2 years after treatment with different strategies.
Measured: 2 years
Aneurysm-related bleeding events
Incidence of aneurysmal-related bleeding events within 2 years after receiving different treatment strategies.
Measured: 2 years
Mortality associated with intracranial aneurysms
Mortality associated with intracranial aneurysms within 2 years after treatment with different strategies
Measured: 2 years
All-cause mortality
All-cause mortality of patients within 2 years after different treatment strategies.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2023
- Study start1 Dec 2021
- Primary completion1 Dec 2024
- Study completion1 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Unruptured Intracranial AneurysmStudies of the same condition, open and under way.
- More trials run by Beijing Tiantan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 31,595 participants (actual)
- Target duration
- 2 Years
Sponsor and investigators
- Lead sponsor
- Beijing Tiantan Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Huashan Hospital, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Fujian Medical University, Shanxi Provincial People's Hospital, Peking University First Hospital, Peking University Third Hospital, Beijing Chao Yang Hospital, Beijing Friendship Hospital, Beijing Hospital, Anhui Provincial Hospital, The First Affiliated Hospital of Anhui Medical University, Binzhou Medical University, The Second Affiliated Hospital of Dalian Medical University, Xijing hospital of The fourth military medical university, Fujian Medical University Union Hospital, The First Dongguan Affiliated Hospital of Guangdong Medical University, First Affiliated Hospital of Guangxi Medical University, The First Affiliated Hospital of Guangzhou Medical University, The second People's Hospital of Guiyang, The Affiliated Hospital Of Guizhou Medical University, Guizhou Provincial People's Hospital, Guilin Medical University, China, National Center for Neurological Disorders (China), First Affiliated Hospital of Harbin Medical University, Changhai Hospital, The Second Affiliated Hospital of Hainan Medical University, The Second Hospital of Hebei Medical University, Wuhan TongJi Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, The First Hospital of Jilin University, Guangzhou Red Cross Hospital, Jiangnan University Medical Center, Xunxian People's Hospital, The Second Affiliated Hospital of Kunming Medical University, First Affiliated Hospital of Kunming Medical University, Lanzhou University Second Hospital, The Southwest Hospital of Army Medical University, Second Affiliated Hospital of Nanchang University, Nanfang Hospital, Southern Medical University, The General Hospital of Eastern Theater Command, Inner Mongolia People's Hospital, General Hospital of Ningxia Medical University, Qinghai People's Hospital, The First Affiliated Hospital of Xiamen University, Qilu Hospital of Shandong University, Qilu Hospital of Shandong University (Qingdao), Qingdao Municipal Hospital, The First Affiliated Hospital of Shanxi Medical University, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Ruijin Hospital, RenJi Hospital, Shenzhen Second People's Hospital, The General Hospital of Northern Theater Command, Xuanwu Hospital, Beijing, West China Hospital, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Soochow University, Tangshan Gongren Hospital, Tianjin Huanhu Hospital, Tianjin Medical University General Hospital, First Affiliated Hospital Xi'an Jiaotong University, Second People's Hospital of Tibet Autonomous Region, Tibet Autonomous Region People's Hospital, Second Xiangya Hospital of Central South University, First Affiliated Hospital of Xinjiang Medical University, The Affiliated Hospital of Xuzhou Medical University, Zhejiang University, Second Affiliated Hospital, Zhejiang University, School of Medicine, Chinese PLA General Hospital, First Hospital of China Medical University, Shengjing Hospital, First Affiliated Hospital, Sun Yat-Sen University, Chongqing General Hospital, First Affiliated Hospital of Chongqing Medical University
- Responsible party
- Principal investigator, Wang Shuo, Beijing Tiantan Hospital
- Investigators
- Wang shuo, M.D., Study chair, Beijing Tiantan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05844163
- Sponsor's protocol ID
- KY2022-226
- Acronym
- ChTUIA
- Status last verified
- Nov 2024
- First submitted
- 25 Apr 2023
- Last updated
- 6 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hou Y, Feng Y, Zhang J, Zheng K, Zhang J, Liu Q, Liu P, Zhang Y, Wu J, Wang S, Zhao D, Chen S. Infection and quality of life after local or full scalp shaving in microsurgical treatment for unruptured intracranial aneurysm sited in anterior circulation. Chin Neurosurg J. 2026 Sep 16;12(1):31. doi: 10.1186/s41016-026-00449-3.
PubMed 42750064Guo R, Wang K, Feng Y, Zheng K, Liu Q, Jiang P, Wu J, Wang S, Tong X. Different duration of dual antiplatelet therapy after endovascular treatment for unruptured intracranial aneurysms. J Clin Neurosci. 2026 Oct;152:112124. doi: 10.1016/j.jocn.2026.112124. Epub 2026 Jun 4.
PubMed 42241917Zheng K, Wen Z, Wang K, Mo S, Wu J, Chen X, Zhao B, Liu Q, Wang S. Treatment strategies for unruptured intracranial aneurysms in the Chinese population: China Treatment Trial for Unruptured Intracranial Aneurysm (ChTUIA). Chin Neurosurg J. 2025 Apr 3;11(1):8. doi: 10.1186/s41016-025-00394-7.
PubMed 40181400
Study at a glance
From the registry record, last updated by the sponsor on 6 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Treatment Strategies for Unruptured Intracranial Aneurysms in the Chinese Population China Treatment Trial for Unruptured Intracranial Aneurysm (ChTUIA)
- ClinicalTrials.gov ID
- NCT05844163
- Acronym / sponsor ID
- ChTUIA / KY2022-226
- Conditions
- Unruptured Intracranial Aneurysm
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 31,595 participants (actual)
- Lead sponsor
- Beijing Tiantan HospitalUniversity, hospital or other
- Collaborators
- Huashan Hospital, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Fujian Medical University, Shanxi Provincial People's Hospital, Peking University First Hospital, Peking University Third Hospital, Beijing Chao Yang Hospital, Beijing Friendship Hospital, Beijing Hospital, Anhui Provincial Hospital, The First Affiliated Hospital of Anhui Medical University, Binzhou Medical University, The Second Affiliated Hospital of Dalian Medical University, Xijing hospital of The fourth military medical university, Fujian Medical University Union Hospital, The First Dongguan Affiliated Hospital of Guangdong Medical University, First Affiliated Hospital of Guangxi Medical University, The First Affiliated Hospital of Guangzhou Medical University, The second People's Hospital of Guiyang, The Affiliated Hospital Of Guizhou Medical University, Guizhou Provincial People's Hospital, Guilin Medical University, China, National Center for Neurological Disorders (China), First Affiliated Hospital of Harbin Medical University, Changhai Hospital, The Second Affiliated Hospital of Hainan Medical University, The Second Hospital of Hebei Medical University, Wuhan TongJi Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, The First Hospital of Jilin University, Guangzhou Red Cross Hospital, Jiangnan University Medical Center, Xunxian People's Hospital, The Second Affiliated Hospital of Kunming Medical University, First Affiliated Hospital of Kunming Medical University, Lanzhou University Second Hospital, The Southwest Hospital of Army Medical University, Second Affiliated Hospital of Nanchang University, Nanfang Hospital, Southern Medical University, The General Hospital of Eastern Theater Command, Inner Mongolia People's Hospital, General Hospital of Ningxia Medical University, Qinghai People's Hospital, The First Affiliated Hospital of Xiamen University, Qilu Hospital of Shandong University, Qilu Hospital of Shandong University (Qingdao), Qingdao Municipal Hospital, The First Affiliated Hospital of Shanxi Medical University, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Ruijin Hospital, RenJi Hospital, Shenzhen Second People's Hospital, The General Hospital of Northern Theater Command, Xuanwu Hospital, Beijing, West China Hospital, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Soochow University, Tangshan Gongren Hospital, Tianjin Huanhu Hospital, Tianjin Medical University General Hospital, First Affiliated Hospital Xi'an Jiaotong University, Second People's Hospital of Tibet Autonomous Region, Tibet Autonomous Region People's Hospital, Second Xiangya Hospital of Central South University, First Affiliated Hospital of Xinjiang Medical University, The Affiliated Hospital of Xuzhou Medical University, Zhejiang University, Second Affiliated Hospital, Zhejiang University, School of Medicine, Chinese PLA General Hospital, First Hospital of China Medical University, Shengjing Hospital, First Affiliated Hospital, Sun Yat-Sen University, Chongqing General Hospital, First Affiliated Hospital of Chongqing Medical University
- Study start
- 1 Dec 2021 (actual)
- Primary completion
- 1 Dec 2024 (actual)
- Study completion
- 1 Dec 2024 (actual)
- First posted
- 6 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this prospective observational cohort study is to learn about treatment strategies for unruptured intracranial aneurysms in the Chinese population. The main questions it aims to answer are:
- To establish a cohort of patients with intracranial unruptured aneurysm and explore the optimal clinical treatment strategy.
- To establish clinical management path for patients with unruptured intracranial aneurysm.
According to the treatment of all patients with unruptured intracranial aneurysm, they were divided into the following groups: 1. Conservative treatment group; 2. Intracranial aneurysm clipping group; 3. Coil embolization or stent-assisted coil embolization group; 4. Flow diversion group.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Intracranial aneurysm clipping group | – | Other: observationPatients in Intracranial aneurysm clipping group receive neurosurgical clipping. |
| Coil embolization or stent-assisted coil embolization group | – | Other: observationPatients in coil embolization or stent-assisted coil embolization group receive coil embolization or stent-assisted coil embolization according to individualized condition. |
| Flow diversion group. | – | Other: observationPatients in flow diversion group receive flow diverters. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with unruptured intracranial aneurysm
Key inclusion criteria (2 listed)
- age > 18 years. B. at least one intracranial aneurysm needs to be treated by craniotomy, endovascular treatment or combined surgery.
- patients' consent were obtained.
Key exclusion criteria (7 listed)
- Ruptured intracranial aneurysms, accompanied by subarachnoid hemorrhage or cerebral hemorrhage ;
- Traumatic, infectious and atrial myxoma-associated intracranial aneurysms ;
- Combined with cerebrovascular malformations;
- Combined with brain tumors or malignant tumors in other parts ;
- Combined with systemic connective tissue disease and systemic rheumatic disease ;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| observationobservation | Other | Coil embolization or stent-assisted coil embolization group, Flow diversion group., Intracranial aneurysm clipping group |
Primary outcome
Primary Outcome
Time frame: 2 years
Functional outcomes(modified Rankin Scale,mRS) at 2 years after treatment decision
6 secondary outcomes
MACCE events
Time frame: 1 years
cardiovascular/cerebrovascular events
Time frame: 2 years
Cost
Time frame: 2 years
Aneurysm-related bleeding events
Time frame: 2 years
Mortality associated with intracranial aneurysms
Time frame: 2 years
All-cause mortality
Time frame: 2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Apr 2026.
- Derived from this study: PubMed 42750064Hou Y, Feng Y, Zhang J, Zheng K, Zhang J, Liu Q, Liu P, Zhang Y, Wu J, Wang S, Zhao D, Chen S. Infection and quality of life after local or full scalp shaving in microsurgical treatment for unruptured intracranial aneurysm sited in anterior circulation. Chin Neurosurg J. 2026 Sep 16;12(1):31. doi: 10.1186/s41016-026-00449-3.
- Derived from this study: PubMed 42241917Guo R, Wang K, Feng Y, Zheng K, Liu Q, Jiang P, Wu J, Wang S, Tong X. Different duration of dual antiplatelet therapy after endovascular treatment for unruptured intracranial aneurysms. J Clin Neurosci. 2026 Oct;152:112124. doi: 10.1016/j.jocn.2026.112124. Epub 2026 Jun 4.
- Derived from this study: PubMed 40181400Zheng K, Wen Z, Wang K, Mo S, Wu J, Chen X, Zhao B, Liu Q, Wang S. Treatment strategies for unruptured intracranial aneurysms in the Chinese population: China Treatment Trial for Unruptured Intracranial Aneurysm (ChTUIA). Chin Neurosurg J. 2025 Apr 3;11(1):8. doi: 10.1186/s41016-025-00394-7.
- Individual participant dataSharing planned: No
Related trials for Unruptured Intracranial Aneurysm
RecruitingObservational study
A Study of Choydar Flow-Directed Mesh Stent in the Treatment of Unruptured Intracranial Aneurysms
Intracranial Aneurysm
Not yet recruiting
Effect of Bilateral Greater Occipital Nerve Block on Headache After Intracranial Aneurysm Coiling
Intracranial Aneurysm, Postoperative Pain
RecruitingObservational study
Evaluation of Intestinal Microbiota Implication in Ruptured Intracranial Aneurysm
Intracranial Sacciform Aneurysm
Not yet recruitingPhase 4
Efficacy and Safety of Methylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intracranial Aneurysms
Unruptured Intracranial Aneurysms, Cerebrovascular Event
RecruitingObservational study
Prospective Observational Cohort Study for Predicting Unruptured Intracranial Aneurysm Rupture Risk Using Blood Pressure Variability and 3D Structural Evolution
Unruptured Intracranial Aneurysm, Intracranial Aneurysm Rupture
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wang shuo, M.D. study chair
Beijing Tiantan Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Unruptured Intracranial Aneurysm, run by Beijing Tiantan Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Outcome (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05844163, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2026.